Overview
Treatment Use of 3,4-Diaminopyridine
Status:
No longer available
No longer available
Trial end date:
1969-12-31
1969-12-31
Target enrollment:
0
0
Participant gender:
All
All
Summary
This protocol has provided 3,4 diaminopyridine (DAP) under a treatment-use IND to patients with congenital myasthenic syndrome (CMS). It is currently closed to enrollment.Details
Lead Sponsor:
Vern C. Juel, M.D.Treatments:
3,4-diaminopyridine
4-Aminopyridine
Amifampridine
Criteria
Inclusion Criteria:- Diagnosis of congenital myasthenic syndrome (CMS)
- Women of childbearing potential must have negative pregnancy test and agree to
practice adequate contraception while taking DAP
- Must be competent to give consent
Exclusion Criteria:
- Known seizure disorder
- Pregnancy
- Known cardiac arrhythmia or evidence of significant arrhythmia on screening ECG
- Known hepatic, renal or hematologic disease